129 related articles for article (PubMed ID: 37260079)
21. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
Hank T; Hinz U; Tarantino I; Kaiser J; Niesen W; Bergmann F; Hackert T; Büchler MW; Strobel O
Br J Surg; 2018 Aug; 105(9):1171-1181. PubMed ID: 29738626
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
23. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
24. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
25. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging.
Liu L; Xu HX; He M; Wang W; Wang WQ; Wu CT; Wei RQ; Liang Y; Gao HL; Liu C; Xu J; Long J; Ni QX; Shao CH; Wang J; Yu XJ
Surgery; 2018 Jun; 163(6):1280-1294. PubMed ID: 29548773
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F
Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
28. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes.
Zhang ML; Kem M; Rodrigues C; Sandini M; Ciprani D; Hank T; Kunitoki K; Qadan M; Ferrone C; Lillemoe K; Fernández-Del Castillo C; Mino-Kenudson M
Histopathology; 2020 Jul; 77(1):144-155. PubMed ID: 31965618
[TBL] [Abstract][Full Text] [Related]
29. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
30. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database.
Kwon W; Heo JS; Han IW; Kang CM; Hwang HK; Kim SC; Park SJ; Yoon YS; Kim YH; Lim CS; Lee SY; Park T; Takami H; Watanabe N; Shimizu Y; Okuno M; Yamaue H; Kawai M; Seiko H; Nagakawa Y; Osakabe H; Sugiura T; Toyama H; Ohtsuka M; Unno M; Endo I; Kitago M; Jang JY
J Hepatobiliary Pancreat Sci; 2023 Sep; 30(9):1129-1140. PubMed ID: 36734142
[TBL] [Abstract][Full Text] [Related]
31. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044
[TBL] [Abstract][Full Text] [Related]
32. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
Cooper AB; Slack R; Fogelman D; Holmes HM; Petzel M; Parker N; Balachandran A; Garg N; Ngo-Huang A; Varadhachary G; Evans DB; Lee JE; Aloia T; Conrad C; Vauthey JN; Fleming JB; Katz MH
Ann Surg Oncol; 2015 Jul; 22(7):2416-23. PubMed ID: 25519927
[TBL] [Abstract][Full Text] [Related]
33. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
34. Robotic and open distal pancreatectomy with celiac axis resection for locally advanced pancreatic body tumors: a single institutional assessment of perioperative outcomes and survival.
Ocuin LM; Miller-Ocuin JL; Novak SM; Bartlett DL; Marsh JW; Tsung A; Lee KK; Hogg ME; Zeh HJ; Zureikat AH
HPB (Oxford); 2016 Oct; 18(10):835-842. PubMed ID: 27506992
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.
Chatterjee D; Katz MH; Foo WC; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
Am J Surg Pathol; 2017 Aug; 41(8):1097-1104. PubMed ID: 28614206
[TBL] [Abstract][Full Text] [Related]
36. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
37. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
Tzeng CW; Fleming JB; Lee JE; Xiao L; Pisters PW; Vauthey JN; Abdalla EK; Wolff RA; Varadhachary GR; Fogelman DR; Crane CH; Balachandran A; Katz MH
Ann Surg Oncol; 2012 Jun; 19(6):2045-53. PubMed ID: 22258816
[TBL] [Abstract][Full Text] [Related]
38. Long-term survivors after pancreatectomy for cancer: the TNM classification is outdated.
Jouffret L; Turrini O; Ewald J; Moutardier V; Iovanna JL; Delpero JR
ANZ J Surg; 2015 Nov; 85(11):860-4. PubMed ID: 26331377
[TBL] [Abstract][Full Text] [Related]
39. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection.
Partelli S; Crippa S; Barugola G; Tamburrino D; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Ann Surg Oncol; 2011 Dec; 18(13):3608-14. PubMed ID: 21584836
[TBL] [Abstract][Full Text] [Related]
40. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
